DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01511185

CompletedPhase 1

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

NNC 90-1170 Mechanism of Action: A Double-blind, Randomized, Single-center, Placebo Controlled, Crossover Study to Examine Beta-cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Healthy volunteers, Type 2 diabetes

Key I/E criterion

•BMI 24-35

Primary endpoint

•AUC of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01511185
Org study IDNN2211-2063

Timeline

Milestones

Study first posted2012-01-18estimated
Last update posted2017-01-26estimated
Study start2001-02 (month precision)
Primary completion2001-10actual (month precision)
Study completion2001-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteersType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months
•Body Mass Index (BMI): 24-35 kg/m^2 inclusive

Exclusion criteria

•SUBJECTS WITH TYPE 2 DIABETES
•Receipt of any investigational drug within three months prior to this trial
•Recurrent severe hypoglycemia as judged by the investigator
•Cardiac disease
•Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level
•Haemoglobin maximum 10 g/L
•HbA1c above 12%
•Loss of more than 400 mL blood during the 3 months prior to trial start
•HEALTHY SUBJECTS
•Receipt of any investigational drug within 3 months prior to this trial
•Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
•Use of any drug that in the investigator's opinion could interfere with the blood glucose level
•Haemoglobin max. 10 g/L
•HbA1c at least 6%

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Safety / tolerability / PK
2

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval

concentration, descriptive

Secondary/protocol endpoint/low confidence

Slope of the mean ISR vs mean glucose

change from baseline, improvement

Secondary/protocol endpoint/low confidence

AUC (area under the curve) of glucagon concentration over the 90-216 mg/dL glucose interval

concentration, descriptive

Secondary/protocol endpoint/low confidence

Insulin Clearance

descriptive

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

NNC 90-1 170 plasma concentration

Plasma concentration (steady state)

concentration, descriptive

Secondary/protocol endpoint

Adverse events

Treatment-emergent AEs (any)

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.